| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On October 23, 2026, Milestone Pharmaceuticals Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common shares was no... |
| 03 Sep 2026 | 8-K: Other Events |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 07 Aug 2026 | SCHEDULE 13G |
| 15 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders |
| 12 Jun 2026 |
Form 4: Giles Lisa M., Director
Granted 77,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Fischer Seth H. Z., Director
Granted 77,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Duty Stuart, Director
Granted 77,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Wills Robert James, Director
Granted 77,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Tomsicek Michael John, Director
Granted 77,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Saik Andrew, Director
Granted 77,000 Stock Option (right to buy) |
| 12 Jun 2026 |
Form 4: Papa Joseph C, Director
Granted 77,000 Stock Option (right to buy) |
| 22 May 2026 | EFFECT |
| 20 May 2026 | CORRESP |
| 18 May 2026 | UPLOAD |
| 15 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 | S-3 |
| 13 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 | 8-K: Results of Operations and Financial Condition |
Loading...
